| Inveox–SEVERAL: investment, 201807c 2nd financing round €5m from four founding business angels |
2018-07-01 |
| Arvinas–Bayer: investment, 201806 founding agricultural 50/50 joint venture w $55m committed funding from Bayer + techn + IP from Arvinas |
2018-06-04 |
| Bayer–Arvinas: PROTAC technology, 201806– collab agricultural 50/50 joint venture w $55m committed funding from Bayer + techn + IP from Arvinas |
2018-06-04 |
| Tricares–Andera Partners: investment, 201806 financing round Series B totalling €22m incl new + co-lead investor Andera Partners |
2018-06-04 |
| Tricares–BioMedPartners: investment, 201806 financing round Series B totalling €22m incl new + co-lead investor BioMed Partners |
2018-06-04 |
| Tricares–CapDecisif: investment, 201806 financing round Series B totalling €22m incl existing + co-investor CapDecisif Management |
2018-06-04 |
| Tricares–Crédit Mutuel-CIC: investment, 201806 financing round Series B totalling €22m incl existing + co-investor CM-CIC Innovation |
2018-06-04 |
| Tricares–GO Capital: investment, 201806 financing round Series B totalling €22m incl existing + co-investor GO Capital |
2018-06-04 |
| Tricares–SEVERAL: investment, 201806 financing round Series B €22m led by Wellington Partners + Andera Partners + BioMedPartners |
2018-06-04 |
| Tricares–Wellington Partners: investment, 201806 financing round Series B totalling €22m incl new + co-lead investor Wellington Partners |
2018-06-04 |
| Qiagen–Freenome: molecular companion diagnostics, 201805– collab co-marketing of CDx solutions for immuno-oncology |
2018-05-31 |
| Corvidia Therapeutics–SEVERAL: investment, 201804 financing round Series B $60m led by Venrock |
2018-04-25 |
| Freenome–Biognosys: proteomic technology, 201804– collab enhancing circulating NA cancer test with proteomics data |
2018-04-24 |
| InterAx Biotech–LeadXPro: cancer immunotherapy, 201804– collab €na drug discovery + optimisation of lead molecules targeting GPCRs |
2018-04-18 |
| Shire–Takeda: investment, 201804–201901 acquisition $62.2b (incl debt approx $80b) for $30.33 per share in cash + 0.839 Takeda shares per share |
2018-04-12 |
| Rebiotix–Ferring: investment, 201804 acquisition of Rebiotix by Ferring |
2018-04-05 |
| Arvinas–Nextech: investment, 201804 financing round Series C totalling $55m incl new + lead investor Nextech Invest |
2018-04-04 |
| Arvinas–SEVERAL: investment, 201804 financing round Series C $55m led by Nextech Invest |
2018-04-04 |
| Abionic–SEVERAL: investment, 201808 financing round Series C CHF20m led by P Bottinelli + incl Investiere AG + ZKB + high net worth individuals |
2018-03-28 |
| T-Knife–Andera Partners: investment, 201803c seed financing round inc investor Andera Partners |
2018-03-14 |
| T-Knife–Boehringer: investment, 201803c seed financing round inc investor BIVF |
2018-03-14 |
| T-Knife–SEVERAL: investment, 201803c seed financing round with Andera Partners + BIVF |
2018-03-14 |
| ImmBioMed–Sekisui: coagulation tests, 201803 acquisiton of specialty coagulation assets of Sekisui Diagnostics GmbH by ImmBioMed |
2018-03-12 |
| Atomwise–SEVERAL: investment, 201803 financing round Series A $45m co-led by Monsanto GV + DCVC (Data Collective) + B Capital Group |
2018-03-07 |
| abcr GmbH–Enzymicals: enzymes, 201803– collab distribution expansion ww catalogue sale of selected enzymes + enzyme-produced chemicals |
2018-03-01 |
| BioMedPartners–SEVERAL: investment, 201805 final closing CHF25m of BioMedInvest III fund bringing total to CHF100m |
2018-03-01 |
| R-Biopharm–Bosch: molecular diagnostics, 201803– collab €na developm tests for Vivalytic platform + sale of system with tests by R-Biopharm |
2018-03-01 |
| Oculis–Bay City Capital: investment, 201801 financing round Series B totalling CHF20m incl new + co-lead investor Bay City Capital |
2018-01-04 |
| Oculis–Brunnur Ventures: investment, 201801 financing round Series B totalling CHF20m incl existing + co-investor Brunnur Ventures |
2018-01-04 |
| Oculis–Huntsworth: public relations, 201801 service existent by Citigate Dewe Rogerson |
2018-01-04 |
| Oculis–Nan Fung: investment, 201801 financing round Series B totalling CHF20m incl new + co-lead investor Pivotal BioVenture Partners |
2018-01-04 |
| Oculis–Novartis: investment, 201801 financing round Series B totalling CHF20m incl new + co-lead investor Novartis Venture Fund |
2018-01-04 |
| Oculis–SEVERAL: investment, 201801 financing round Series B CHF20m led by Bay City Capital + NVF + Pivotal BioVenture Partners |
2018-01-04 |
| Oculis–Silfurberg: investment, 201801 financing round Series B totalling CHF20m incl existing + co-investor Silfurberg |
2018-01-04 |
| Aquila Biolabs–Germany (govt): investment, 2018 financing round pre-Series A totalling 7-digit € incl investor KfW Bankengruppe |
2018-01-01 |
| Aquila Biolabs–PERSON: investment, 2018 financing round pre-Series A totalling 7-digit € incl investor Jürgen Schumacher |
2018-01-01 |
| Aquila Biolabs–PERSON: investment, 2018 financing round pre-Series A totalling 7-digit € incl investor Robert Huber |
2018-01-01 |
| Aquila Biolabs–Seed Fonds Aachen: investment, 2018 financing round pre-Series A totalling 7-digit € incl investor Seed Fonds Aachen II |
2018-01-01 |
| Aquila Biolabs–SEVERAL: investment, 2018 financing round pre-Series A 7-digit € from Seed Fonds Aachen II + KfW + J Schumacher + R Huber |
2018-01-01 |
| Century Therapeutics–Fujifilm: iPSC technnology, 2018– collab developm iPSC-derived immune effector cells for cancer + license + supply by FDCI |
2018-01-01 |
| CRISPR Therapeutics–ViaCyte: regenerative medicine, 2018– collab incl gene-edited allogeneic stem cell-derived therapies for type 1 diabetes |
2018-01-01 |
| Dopavision–Germany (govt): grant, 2018– BMBF grant €1.4m over 3 years |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–AstraZeneca: oligonucleotide drugs, 2018– collab AstraZeneca is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–Biogen: oligonucleotide drugs, 2018– collab Biogen is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–GSK: oligonucleotide drugs, 2018– collab GSK is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–JnJ: oligonucleotide drugs, 2018– collab Janssen is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–Pfizer: oligonucleotide drugs, 2018– collab Pfizer is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–Roche: oligonucleotide drugs, 2018– collab Roche is founding member of EPOC |
2018-01-01 |
| European Pharma Oligonucleotide Consortium–Sanofi: oligonucleotide drugs, 2018– collab Sanofi is founding member of EPOC |
2018-01-01 |
| Exum Instruments–Elemental Scientific: Massbox, 2018– TOFwerk + ESI join as equity partners to design + produce first instrument |
2018-01-01 |
| Exum Instruments–TOFwerk: investment, 2018 TOFwerk + ESI join as equity partners to design + produce first instrument |
2018-01-01 |
| Exum Instruments–TOFwerk: Massbox, 2018– TOFwerk + ESI join as equity partners to design + produce first instrument |
2018-01-01 |
| MedXCell–SEVERAL: investment, 2018 seed financing round CHF1.5m |
2018-01-01 |
| Pfizer–BioNTech: mRNA-based vaccines, 2018– collab development of influenza vaccines |
2018-01-01 |
| ThinqLab–Holtzbrinck: investment, 2018 investment by Digital Science becoming part-owner of Writefull |
2018-01-01 |
| Roche–DiCE Molecules: small-molecule drug discovery, 201712– multi-year research collab €na using DiCE technology with Genentech |
2017-12-19 |
| Institut Virion\Sirion–ExpreS2ion Biotech: expression technology, 201712– collab using ExpreS2 platform for antigen production for IVD tests |
2017-12-04 |
| Anaveon–Basel (govt): investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch |
2017-12-01 |
| Anaveon–SEVERAL: investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch |
2017-12-01 |
| Anaveon–Univ Zurich: investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch |
2017-12-01 |
| SimLeap project–Bicoll: sweetener, 201711–2019 collab Bicoll is project partner |
2017-11-17 |
| SimLeap project–Charité: sweetener, 201711–2019 collab Charité is project partner |
2017-11-17 |
| SimLeap project–Germany (govt): grant, 201711–2019 BMB funding €1.1m out of total project volume of €1.6m |
2017-11-17 |
| SimLeap project–Symrise: sweetener, 201711–2019 collab Symrise is project partner |
2017-11-17 |
| Body Labs–Amazon: investment, 201710 acquisition €na (estimate $50m-$70m) of Body Labs by Amazon |
2017-10-03 |
| Labiotech.eu–SEVERAL: investment, 201709 2nd financing round €6-digit led by Wille AG + incl Simon Bungers |
2017-09-18 |
| Labiotech.eu–Wille Finance: investment, 201709 2nd financing round totalling €6-digit incl new + lead investor Wille AG |
2017-09-18 |
| GreenLight Biosciences–SEVERAL: investment, 201709 financing round Series D $18m led by Fall Line Capital |
2017-09-13 |
| Repare Therapeutics–SEVERAL: investment, 201706 financing round Series A $68m co-led by Versant Ventures + MPM Capital |
2017-06-22 |
| Hopp Group–CRS Clinical Research Services: investment, 201706 management buy-out of CRS from LTS via holding Apleonex AG |
2017-06-19 |
| Kaken Pharmaceutical–Numab: therapeutic antibody, 201706– collab + license option €na for multispecific antibody for inflammatory disease |
2017-06-13 |
| Waters–Andrew Alliance: automated liquid handling technology, 201706– collab co-marketing semi-automated sample prep solution |
2017-06-01 |
| Cardior Pharmaceuticals–BioMedPartners: investment, 201705 financing round Series A totalling €15m incl co-lead investor BioMedInvest III Fund |
2017-05-11 |
| Cardior Pharmaceuticals–BMS: investment, 201705 financing round Series A totalling €15m incl co-lead investor BMS |
2017-05-11 |
| Cardior Pharmaceuticals–Boehringer: investment, 201705 financing round Series A totalling €15m incl co-lead investor BIVF |
2017-05-11 |
| Cardior Pharmaceuticals–High-Tech Gründerfonds: investment, 201705 financing round Series A totalling €15m incl co-lead investor HTGF |
2017-05-11 |
| Cardior Pharmaceuticals–Life Sciences Partners: investment, 201705 financing round Series A totalling €15m incl co-lead investor LSP |
2017-05-11 |
| Elitech–PAI Partners: investment, 201705– acquisition of Elitech Group by PAI Partners from Ergon Capital Partners |
2017-05-11 |
| Caladrius–Hitachi: investment, 201705 acquisition of PCT LLC by Hitachi Chemical |
2017-05-01 |
| TolerogenixX–Germany (govt): grant, 201705 BMWi Exist Forschungstransfer grant €1.4m |
2017-05-01 |
| Sinopharm–Oncgnostics: molecular diagnostics, 201704– license excl for Gyntect test to CJMT/GeneoDx for China + Hong Kong + Macao |
2017-04-05 |
| Draupnir Bio–High-Tech Gründerfonds: investment, 201704 seed financing round totalling DKK15m (€2m) inkl investor HTGF |
2017-04-01 |
| Draupnir Bio–SEVERAL: investment, 201704 seed financing round DKK15m (€2m) from Novo Seeds + HTGF |
2017-04-01 |
| Axolabs–LGC: investment, 201703 acquisition of Axolabs GmbH by LGC |
2017-03-01 |
| Merck (DE)–Palantir: data integration and analysis s/w, 201701– collab €na use initially in healthcare ultimately in all 3 business sectors of Merck |
2017-01-12 |
| ArchiMed–SEVERAL: investment, 2017 closing of MED II Fund at €315m |
2017-01-01 |
| Cutiss–Univ Zurich: investment, 2017 seed funding from UZH Life Sciences Fund |
2017-01-01 |
| Inveox–SEVERAL: investment, 2017 seed financing round €1m from four business angels |
2017-01-01 |
| Mestex–SEVERAL: investment, 2017 2nd financing round |
2017-01-01 |
| Swixx Biopharma–HBM: investment, 2017 initial investment of HBM Healthcare Investments in Swixx Biopharma AG |
2017-01-01 |
| Xpand Biotechnology–Kuros: investment, 201612 merger acquisition of Xpand Biotechnology BV by Kuros Biosciences AG for up to 2.105m new Kuros shares |
2016-12-19 |
| Phlexglobal–Vitruvian Partners: investment, 201612 investment by VIP II |
2016-12-01 |
| T3 Pharmaceuticals–OTHER: investment, 201611 1st financing round from private Swiss investors |
2016-11-23 |
| Celonis–SEVERAL: investment, 201606 financing round Series A $27.5m |
2016-06-01 |
| Labiotech.eu–WestTech Ventures: investment, 201602 seed financing round totalling low €6-digit incl lead investor WestTech Ventures |
2016-02-03 |
| Mecuris–Bavaria (govt): investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
| Mecuris–High-Tech Gründerfonds: investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
| Mecuris–SEVERAL: investment, 2016c seed financing round from Bayern Kapital + HTGF |
2016-01-01 |
| AdvanDx–OpGen: investment, 201507 merger acquisition by AdvanDx for 682k shares of OpGen common stock |
2015-07-14 |
| Macrolide–Bertarelli Group: investment, 201503 financing round Series A totalling $22m inc co-lead investor Gurnet Point Capital |
2015-03-04 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 39 40 41 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
